ALKERMES | ALKS - Cash And Equivalent

Stock Price
34.32
Daily Change
-0.64 -1.83%
Monthly
22.57%
Yearly
9.65%
Q1 Forecast
32.88

ALKERMES reported $616.45M in Cash and Equivalent for its fiscal quarter ending in September of 2025.





Cash And Equivalent Change Date
AbbVie USD 5.63B 838M Sep/2025
Acadia Pharmaceuticals USD 847.02M 85.02M Sep/2025
ALKERMES USD 616.45M 95.25M Sep/2025
Amgen USD 9.44B 1.42B Sep/2025
Biogen USD 3.86B 1.1B Sep/2025
BioMarin Pharmaceutical USD 1.25B 36.29M Sep/2025
Bristol-Myers Squibb USD 15.73B 3.13B Sep/2025
Eli Lilly USD 9.79B 6.42B Sep/2025
Gilead Sciences USD 5.14B 2.78B Jun/2025
Ionis Pharmaceuticals USD 2.24B 1.94B Sep/2025
J&J USD 18.23B 10.35B Sep/2025
Malin Corporation EUR 62.1M 26.4M Dec/2024
Merck USD 18.17B 10.16B Sep/2025
Neurocrine Biosciences USD 340.2M 76.2M Sep/2025
Otsuka Holdings JPY 411.11B 3.62B Jun/2025
Pfizer USD 1.34B 295M Sep/2025
Regeneron Pharmaceuticals USD 18.87B 16.36B Dec/2025
Vertex Pharmaceuticals USD 6.29B 95.8M Sep/2025